Construction d'un clone produisant des vecteurs rétroviraux s'auto-inactivant pour le traitement de l'épidermolyse bulleuse dystrophique récessive par thérapie génique
|Advisor:||Caruso, Manuel; Germain, Lucie|
|Abstract:||Recessive dystrophic epidermolysis bullosa is a rare genetic disorder caused by mutations in COL7A1 encoding type VII collagen. This protein is produced by the epidermal keratinocytes and dermal fibroblasts and allows the formation of anchor fibrils whose role is the adhesion of the epidermis to the underlying dermis. Patients with EBDR suffer from skin and mucosal detachments and no treatment can cure this disease. The goal of this project is to construct a safe viral vector containing COL7A1 cDNA and to generate a high-titer virus-producing cell clone in order to transduce enough keratinocytes stem cells to produce reconstructed skins to treat patients with EBDR. Various self-inactivated retroviral vectors expressing gfp or COL7A1 cDNA have been generated. The GFP vectors allowed us to determine that the replacement of the U3 region of the 5' LTR by the CMV enhancer and promoter, the addition of the WPRE sequence to the 3 'UTR of the transgene, the insertion of the SV40 polyadenylation sequence into the R region of 3' LTR and the addition of the polyadenylation sequence of the bGH downstream of the 3' LTR generate the highest viral titers. COL7A1 cDNA was introduced into an optimized SIN retrovirus and transfected into a packaging cell line expressing the Amphotropic envelope 4070A. A clone of packaging cells producing 9.8 x 105 viral particles per mL was isolated. The virus produced by this clone is capable of transducing the keratinocytes and fibroblasts of patients with EBDR at a transduction rate of 37 % and 20 % respectively. In sum, a clone of cells producing a safe COL7A1 retroviral vector has been generated and has the potential of being used for gene therapy of EBDR.|
|Document Type:||Mémoire de maîtrise|
|Open Access Date:||24 April 2019|
|Collection:||Thèses et mémoires|
All documents in CorpusUL are protected by Copyright Act of Canada.